Abstract:For years, immunotherapy has been considered a viable and attractive treatment option for patients with cancer. Among the immunotherapy arsenal, the targeting of intratumoral immune cells by immune-checkpoint inhibitory agents has recently revolutionised the treatment of several subtypes of tumours. These approaches, aimed at restoring an effective antitumour immunity, rapidly reached the market thanks to the simultaneous identification of inhibitory signals that dampen an effective antitumor response in a large variety of neoplastic cells and the clinical development of monoclonal antibodies targeting checkpoint receptors. Leading therapies in solid tumours are mainly focused on the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) pathways. These approaches have found a promising testing ground in both Hodgkin lymphoma and non-Hodgkin lymphoma, mainly because, in these diseases, the malignant cells interact with the immune system and commonly provide signals that regulate immune function. Although several trials have already demonstrated evidence of therapeutic activity with some checkpoint inhibitors in lymphoma, many of the immunologic lessons learned from solid tumours may not directly translate to lymphoid malignancies. In this sense, the mechanisms of effective antitumor responses are different between the different lymphoma subtypes, while the reasons for this substantial difference remain partially unknown. This review will discuss the current advances of immune-checkpoint blockade therapies in B-cell lymphoma and build a projection of how the field may evolve in the near future. In particular, we will analyse the current strategies being evaluated both preclinically and clinically, with the aim of fostering the use of immune-checkpoint inhibitors in lymphoma, including combination approaches with chemotherapeutics, biological agents and/or different immunologic therapies.

Immune-Checkpoint Inhibitors in B-Cell Lymphoma

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Immune checkpoint blockade in hematological malignancies: current state and future potential

B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune Checkpoint Inhibitors And Cellular Treatment For Lymphoma Immunotherapy

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Checkpoint inhibition in hematologic malignancies

[Immune-checkpoints: the new anti-cancer immunotherapies]

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Immune Checkpoints in Cancers: From Signaling to the Clinic

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current Knowledge

Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment

Immune checkpoint: The novel target for antitumor therapy

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives